MET Y1003X mutations, which abolish the binding domain of the E3 ubiquitin-protein ligase, c-CBL, disrupt degradation, and prolong the activation of MET signaling, are extremely rare and are far below 0.1% in lung cancers [16]. This evidence concerns the gene MET and lung carcinoma.